1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

11 May 2024
Admin
News Article

Arcellx and Kite Continue Anito-Cel Multiple Myeloma Program

Arcellx and Kite Continue Progress with Advances in Anito-Cel Multiple Myeloma Program

Overview

Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have jointly announced significant operational advancements in their collaborative effort on the anitocabtagene autoleucel (anito-cel) program for multiple myeloma treatment. This innovative therapy, utilizing Arcellx's compact D-Domain binder, represents a breakthrough as the first BCMA CAR T therapy explored in multiple myeloma.

iMMagine-3 trial

The focal point of these updates is the unveiling of the iMMagine-3 trial, a global Phase 3 randomized controlled clinical trial.
Expected to commence in the latter half of this year, this trial aims to compare the efficacy and safety of anito-cel against the current standard of care (SOC) for patients with relapsed and/or refractory multiple myeloma (rrMM).
These patients will have undergone one to three prior lines of therapy, including both an immunomodulatory drug (IMiD) and an anti-CD38 monoclonal antibody.

Manufacturing for Trial

Manufacturing for this trial will take place at Kite's facility in Frederick, Maryland, following the successful technical transfer from a third-party manufacturing organization.
Additionally, the Investigational New Drug (IND) application for anito-cel has received clearance from the U.S. Food and Drug Administration.

Words from CEO: Arcellx

Rami Elghandour, Arcellx’s Chairman and CEO, emphasized the significance of the iMMagine-3 trial in addressing an unmet clinical need, particularly in patients who have been exposed to previous treatments. He highlighted the trial's ability to capture a substantial patient population and provide access to a unique segment of patients.

Kite on Unmet Needs

Kite, underscored the urgency of addressing the substantial unmet need in patients with relapsed and/or refractory multiple myeloma. She expressed confidence in leveraging Kite's manufacturing expertise to position anito-cel as a leading candidate in cell therapy.

The iMMagine-3 trial is designed to enroll approximately 450 adult patients across ~130 study sites globally. Patients randomized to the anito-cel arm will undergo a specific treatment regimen involving leukapheresis, optional bridging therapy, lymphodepleting chemotherapy, and infusion of anito-cel.

The Endpoints

The primary endpoint of the trial is progression-free survival (PFS), with key secondary endpoints including complete response rate, minimal residual disease negativity, overall survival, and safety parameters.

Collaborative Effort

• The collaborative effort between Arcellx and Kite aims to co-develop and co-commercialize anito-cel for the treatment of relapsed or refractory multiple myeloma.
• Anito-cel's unique characteristics, including its novel D-Domain binder and regulatory designations, position it as a promising candidate in the treatment landscape.